Brokers Set Expectations for AC Immune FY2027 Earnings

AC Immune SA (NASDAQ:ACIU - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2027 earnings per share estimates for AC Immune in a report released on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.12. The consensus estimate for AC Immune's current full-year earnings is ($0.89) per share.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.67). The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $91.60 million.

ACIU has been the topic of several other research reports. StockNews.com cut AC Immune from a "buy" rating to a "hold" rating in a report on Tuesday, October 1st. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of AC Immune in a report on Wednesday.

AC Immune Stock Up 5.5 %

ACIU traded up $0.17 during trading on Thursday, reaching $3.26. The stock had a trading volume of 70,257 shares, compared to its average volume of 347,366. The firm has a market capitalization of $322.54 million, a price-to-earnings ratio of -4.29 and a beta of 1.28. AC Immune has a 1-year low of $2.25 and a 1-year high of $5.14. The stock has a 50 day moving average of $3.27 and a two-hundred day moving average of $3.45.

Hedge Funds Weigh In On AC Immune

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in shares of AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company's stock valued at $2,602,000 after acquiring an additional 136,300 shares in the last quarter. Assenagon Asset Management S.A. increased its position in AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company's stock worth $1,755,000 after buying an additional 328,312 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock valued at $33,000 after acquiring an additional 8,423 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of AC Immune in the first quarter worth $30,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock worth $72,000 after purchasing an additional 7,400 shares during the period. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.